The estimated Net Worth of Norbert G Riedel is at least 8.46 百万$ dollars as of 11 August 2023. Norbert Riedel owns over 1,241 units of Aptinyx Inc stock worth over 836$ and over the last 22 years he sold APTX stock worth over 2,819,172$. In addition, he makes 5,635,420$ as President、 Chief Executive Officer、 Director at Aptinyx Inc.
Norbert has made over 24 trades of the Aptinyx Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 1,241 units of APTX stock worth 171,457$ on 11 August 2023.
The largest trade he's ever made was exercising 380,000 units of Aptinyx Inc stock on 17 May 2021 worth over 23,180$. On average, Norbert trades about 13,347 units every 78 days since 2003. As of 11 August 2023 he still owns at least 13,705 units of Aptinyx Inc stock.
You can see the complete history of Norbert Riedel stock trades at the bottom of the page.
Dr. Norbert G. Riedel Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Riedel previously served as Chief Executive Officer and President of Naurex Inc., our predecessor company, from January 2014 to July 2015. From 2001 to January 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel also serves on the board of directors of Jazz Pharmaceuticals plc, Eton Pharmaceuticals, Inc., Cerevel Therapeutics, Inc., and the Illinois Biotechnology Innovation Organization and is also a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel previously served as an associate professor of medicine at Boston University School of Medicine and a visiting associate professor at the Massachusetts Institute of Technology. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt. Dr. Riedel brings significant scientific, drug discovery and development, and commercial expertise to our board of directors with over 20 years of experience in the biotechnology and pharmaceutical industries.
As the President、 Chief Executive Officer、 Director of Aptinyx Inc, the total compensation of Norbert Riedel at Aptinyx Inc is 5,635,420$. There are no executives at Aptinyx Inc getting paid more.
Norbert Riedel is 62, he's been the President、 Chief Executive Officer、 Director of Aptinyx Inc since 2015. There are 2 older and 8 younger executives at Aptinyx Inc. The oldest executive at Aptinyx Inc is Elisha Gould, 63, who is the Independent Director.
Norbert's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 6 years, insiders at Aptinyx Inc have traded over 0$ worth of Aptinyx Inc stock and bought 10,337,357 units worth 55,328,087$ . The most active insiders traders include Street Partners Llc Adams、Patrick G Enright、James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of 18,161$. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth 50,091$.
welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.
Aptinyx Inc executives and other stock owners filed with the SEC include: